Figure 3.

ALKBH5 Increased Sensitivity to Cisplatin In Vivo and In Vitro

(A) Knockdown of ALKBH5 expression decreased the suppression rate of cisplatin and increased IC₅₀ to cisplatin in 5637 and T24 cells by CCK-8. Data represent the mean ± SD from three independent experiments, ∗p < 0.05. (B) Overexpression of ALKBH5 expression increased the rate of cisplatin and decreased IC₅₀ to cisplatin in 5637 and T24 cells by CCK-8. Data represent the mean ± SD from three independent experiments, ∗p < 0.05. (C–E) The percentage of apoptotic cells was increased after treatment with cisplatin for 48 h. Knockdown of ALKBH5 expression decreased the rate of cisplatin-induced apoptosis compared with control cells in 5637 and T24 cells, whereas overexpression of ALKBH5 increased the rate of cisplatin-induced apoptosis. Data represent the mean ± SD from three independent experiments. Student’s t test with two biological independent replicates was used to determine statistical significance, ∗p < 0.05. (F and G) Subcutaneous xenograft tumor model with ALKBH5 knockdown (shALKBH5) or control cells (shNC). Cisplatin or normal saline was injected intraperitoneally starting from day 7 of tumor inoculation. The red arrows indicate the location of the tumor. (H) Tumor weight was measured after 3 weeks from transplanting. Data represent the mean ± SD, ∗p < 0.05. (I) Tumor volume was measured every 3 days from transplanting. Data represent the mean ± SD, ∗p < 0.05.